UID:
almahu_9949983320502882
Umfang:
1 online resource (198 pages)
Ausgabe:
1st ed.
ISBN:
9780443134524
,
0443134529
Anmerkung:
Front Cover -- Onco-Palliative Care Essentials -- Onco-Palliative Care Essentials -- Copyright -- Dedication -- Contents -- About the authors -- Acknowledgments -- 1 - Oncopalliative care essentials -- Objectives -- 2 - Introduction to oncopalliative care -- 1. Introduction -- 2. Early integration of palliative care -- 3. Oncopalliative care: an multidisciplinary team approach -- 4. Oncopalliative care-objectives -- 5. The focus of this book -- References -- 3 - Common symptoms and management in oncopalliative care -- 1. Pain -- 1.1 Introduction -- 1.2 Definition of pain -- 1.3 A brief overview of cancer pain and its significance in oncopalliative care -- 1.4 Total pain -- 1.5 Other common types of cancer pain -- 1.6 Physiology of cancer pain -- 1.7 Cancer pain syndromes -- 1.8 Importance of managing cancer pain -- 1.9 Opioid receptors and the mechanism of their action -- 1.10 Common terminologies and definitions regarding opioids -- 1.11 Assessment of cancer pain -- 1.12 The pain assessment tools and "OPQRSTUV" rule of pain assessment -- 1.12.1 World Health Organization analgesic ladder for cancer pain -- 1.13 Management of cancer pain -- 1.13.1 General principles in cancer pain management -- 1.13.2 Management of mild pain (step 1) -- 1.13.3 Management of mild to moderate pain (step 2) -- 1.13.4 Management of moderate to severe pain (step 3) -- 1.13.5 Management of cancer pain with nonpharmacological measures (step 4) -- 1.13.5.1 Nonpharmacological therapies -- 1.13.5.1.1 Palliative radiotherapy -- 1.13.5.1.2 Physical therapy -- 1.13.5.1.3 Occupational therapy -- 1.13.5.1.4 Psychological support -- 1.13.5.1.5 Acupuncture -- 1.13.5.1.6 Hypnotherapy -- 1.13.5.1.7 Music and art therapy -- 1.13.5.1.8 Spiritual support -- 1.13.5.2 Interventional therapies -- 1.13.5.2.1 Nerve and neurolytic blocks -- 1.13.5.2.2 Radiofrequency ablation.
,
1.13.5.2.3 Spinal cord stimulation -- 1.13.5.2.4 Surgical interventions -- 1.13.5.2.5 Cryoablation -- 1.13.5.2.6 Percutaneous cordotomy -- 1.13.5.2.7 Hyperthermia -- 1.13.6 Management of neuropathic pain in cancer patients -- 1.13.6.1 Practical steps in treating cancer-related neuropathic pain -- 1.13.6.1.1 First-line recommendation -- 1.13.6.1.2 Second-line recommendation -- 1.13.6.1.3 Third-line recommendation -- 1.13.6.1.4 Fourth-line recommendation (nonpharmacological interventions) -- 1.13.7 Special considerations for liver and renal impairment -- 1.13.8 Special considerations for elderly and cachectic patients -- 1.13.9 Opioid toxicity -- 1.13.9.1 Symptoms of opioid toxicity -- 1.13.9.2 Management of opioid toxicity -- 1.13.10 Barriers to pain management in cancer patients -- 1.13.11 The future direction of cancer pain management -- 2. Anxiety -- 2.1 Definition -- 2.2 Types of anxiety disorders -- 2.3 Prevalence of anxiety -- 2.4 Assessment of anxiety -- 2.5 Nonpharmacologic management of anxiety -- 2.6 Pharmacological interventions -- 2.7 Summary and conclusions -- 3. Depression -- 3.1 Definition -- 3.2 Prevalence -- 3.3 Assessment of depression -- 3.4 Nonpharmacologic management of depression -- 3.5 Pharmacologic management of depression -- 3.6 Summary and conclusions -- 4. Nausea and vomiting -- 4.1 Definition -- 4.2 Prevalence -- 4.3 Etiology and pathophysiology -- 4.3.1 Radiation therapy-induced nausea and vomiting -- 4.3.2 Chemotherapy-induced nausea and vomiting -- 4.4 Pathophysiology of nausea and vomiting -- 4.5 Clinical assessment of nausea and vomiting -- 4.6 Management of nausea and vomiting -- 4.6.1 Pharmacological management of nausea and vomiting based on etiology approach -- 4.6.1.1 Chemotherapy-induced nausea and vomiting -- 4.6.1.2 Radiation-induced nausea and vomiting -- 4.6.1.3 Intracranial lesion.
,
4.6.1.4 Malignant bowel obstruction -- 4.6.1.5 Anticipatory nausea and vomiting -- 4.6.1.6 Treatment of refractory nausea and vomiting -- 4.6.2 Nonpharmacological management of nausea and vomiting -- 4.7 Summary and conclusions -- 5. Anorexia-cachexia syndrome -- 5.1 Definition -- 5.2 Prevalence -- 5.3 Impact of anorexia-cachexia syndrome -- 5.4 Etiology and pathophysiology of anorexia-cachexia syndrome -- 5.5 Assessment of anorexia-cachexia syndrome -- 5.6 Treatment of anorexia-cachexia syndrome -- 5.6.1 General aspects of treatment -- 5.6.2 Pharmacologic management of ACS -- 5.6.2.1 Megestrol acetate -- 5.6.2.2 Glucocorticoids -- 5.6.2.3 Anabolic steroids -- 5.6.2.4 Treatment of gastroparesis -- 5.6.2.5 Cannabis and cannabinoids -- 5.6.2.6 Omega-3 fatty acids/EPA and DHA -- 5.6.2.7 Amino acids/carnitine supplements -- 5.6.2.8 Nonsteroidal antiinflammatory drugs/COX-2 selective inhibitors -- 5.6.2.9 Mirtazapine -- 5.6.2.10 Growth hormone and ghrelin -- 5.6.2.11 Combination therapy -- 5.6.3 Nonpharmacologic treatment of ACS -- 5.6.3.1 Artificial nutritional support -- 5.7 Summary and recommendations -- 6. Cancer-related fatigue -- 6.1 Definition -- 6.2 Prevalence -- 6.3 Etiology -- 6.3.1 Setting-specific causes -- 6.3.2 Disease-specific causes -- 6.3.3 Other causes -- 6.4 Assessment of cancer-related fatigue -- 6.5 Impact on patients with advanced cancer -- 6.6 Nonpharmacological management of cancer-related fatigue -- 6.7 Pharmacological treatment -- 6.7.1 Treatment of anemia -- 6.7.2 Treatment of sleep disturbance -- 6.7.3 Polypharmacy and the possibility of drug-drug interaction -- 6.7.4 Avoiding opioid-induced side effects -- 6.7.5 Adequate control of advanced cancer-associated symptoms -- 6.7.6 Medications used in the treatment of CRF without a known underlying cause -- 6.7.6.1 Methylphenidate -- 6.7.6.2 Modafinil -- 6.7.6.3 Corticosteroids.
,
6.8 Summary and conclusions -- 7. Dyspnea -- 7.1 Definition -- 7.2 Prevalence of dyspnea -- 7.3 Assessment of dyspnea -- 7.4 Total Dyspnea -- 7.5 Management of dyspnea -- 7.5.1 Nonpharmacological management of dyspnea -- 7.5.1.1 Low-intensity exercise -- 7.5.1.2 Handheld fan -- 7.5.1.3 Energy preservation -- 7.5.1.4 Complementary therapy -- 7.5.1.5 Oxygen and ventilation in dyspnea -- 7.5.2 Pharmacologic management of dyspnea -- 7.5.2.1 Opioids -- 7.5.2.2 Benzodiazepines -- 7.5.2.3 Corticosteroids -- 7.5.2.4 Bronchodilators -- 7.5.2.5 Palliative sedation -- 7.6 Summary and conclusions -- 8. Delirium -- 8.1 Definition -- 8.2 Prevalence of delirium -- 8.3 Causes of delirium -- 8.4 Assessment of delirium -- 8.5 Management of delirium -- 8.5.1 Nonpharmacological management -- 8.5.2 Pharmacologic management -- 8.5.3 Summary and conclusions -- AI disclosure -- References -- 4 - Common emergencies in oncopalliative care -- 1. Introduction -- 2. Airway obstruction -- 2.1 Introduction -- 2.2 Causes -- 2.3 Presentation -- 2.4 Assessment -- 2.5 Management -- 3. Malignant bowel obstruction -- 3.1 Introduction -- 3.2 Causes -- 3.3 Presentation -- 3.4 Assessment -- 3.5 Management -- 3.5.1 Opioid analgesics -- 3.5.2 Antiemetics -- 3.5.3 Octreotide -- 3.5.4 Corticosteroids -- 3.5.5 Bowel decompression -- 3.5.6 Hydration and nutrition -- 4. Massive hemorrhage -- 4.1 Introduction -- 4.2 Common causes -- 4.3 Presentation -- 4.4 Assessment -- 4.5 Management -- 4.5.1 Immediate measures -- 4.5.2 Hemodynamic stabilization -- 4.5.3 Blood product transfusions -- 4.5.4 Control bleeding source -- 4.5.5 Pharmacological interventions -- 4.5.6 Symptomatic management -- 4.5.7 Collaborative approach -- 4.5.8 Emotional and spiritual support -- 5. Superior vena cava syndrome -- 5.1 Introduction -- 5.2 Causes -- 5.3 Presentation -- 5.3.1 Hemodynamic symptoms.
,
5.3.2 Respiratory symptoms -- 5.3.3 Neurological symptoms -- 5.4 Diagnosis -- 5.5 Management -- 5.6 Oncopalliative care approach -- 6. Neoplastic spinal cord compression -- 6.1 Introduction -- 6.2 Causes -- 6.3 Presentation -- 6.4 Assessment -- 6.4.1 Clinical history -- 6.4.2 Physical examination -- 6.4.3 Diagnostic imaging -- 6.4.4 Laboratory tests -- 6.4.5 Biopsy -- 6.5 Management -- 6.5.1 Emergency stabilization -- 6.5.2 Corticosteroids -- 6.5.3 Radiation therapy -- 6.5.4 Surgery -- 6.5.5 Chemotherapy -- 6.5.6 Pain management -- 6.5.7 Rehabilitation -- 6.5.8 Follow-up monitoring -- AI disclosure -- References -- 5 - "End-of-life care"-An art and science -- 1. "End-of-life care"-Introduction -- 2. The role of communication in end-of-life care -- 3. Prognostication -- 4. Palliative versus hospice care -- 5. Advance care planning, advance directives, DNAR, and AND -- 6. Legal and ethical considerations in end-of-life care -- 7. Cultural and spiritual considerations in end-of-life care -- 8. Terminal phase of life -- 9. Grief and bereavement -- 10. Outcome variables that determine the quality of end-of-life care and experience -- AI disclosure -- References -- Further reading -- 6 - Psychosocial aspects in oncopalliative care -- 1. Psychosocial care-an introduction -- 2. Psychosocial assessment in oncopalliative care -- 3. Psychosocial distress and its diagnosis -- 4. Oncopalliative care triangle for psychosocial support -- 5. Benefits of psychosocial care -- 6. Management of psychosocial distress -- AI disclosure -- References -- 7 - Ethical and legal practices in oncopalliative care -- 1. Ethical aspects in oncopalliative care -- 2. The paternalistic approach to palliative care -- 3. The shared decision-making model -- 4. Determining what is in the best interest of the patients -- 5. The patient's surrogate -- 6. Working with surrogates.
,
7. Futility.
Weitere Ausg.:
ISBN 9780443134517
Weitere Ausg.:
ISBN 0443134510
Sprache:
Englisch
Bookmarklink
